IntelGenx creates scientific advisory board

Friday, February 5, 2016

IntelGenx has created a scientific advisory board with the engagement of Dr. Ludwig Aigner and Dr. Barry Greenberg. Dr. Horst G. Zerbe will act as the chairman and Nadine Paiement (vice president, R&D) will serve as vice-chair of the scientific advisory board. 

[Read More]

FDA approves high dose anti-depressant

Thursday, November 17, 2011

The FDA has approved IntelGenx’ lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.

[Read More]